Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8656970 | Atherosclerosis | 2018 | 7 Pages |
Abstract
ASA is the only drug that affects the amplitude of CIV response observed after galvanic current application to the skin of vascular patients. CIV depends on BMI but not age or gender. As such, CIV appears to be a potential objective marker of ASA intake and could facilitate future non-invasive assessments of adherence to ASA treatment.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Anne-Sophie Florczak, Samir Henni, Isabelle Signolet, Jean-François Hamel, Anne Humeau-Heurtier, Pascal Rousseau, Pierre Abraham,